Table 1.
Baseline characteristics of patients.
| Total | Training | Validation | P | |
|---|---|---|---|---|
| Age (years) | N = 505 (100(%)) | 504 | ||
| <50 | 512 (51%) | 259 (51.29%) | 253 (50.2%) | 0.78 |
| ≥50 | 497 (49%) | 246 (48.71%) | 251 (49.8%) | |
| Histological grade | N = 505 (100(%)) | |||
| I | 52 (5%) | 25 (4.95%) | 27 (5.36%) | 0.96 |
| II | 686 (68%) | 344 (68.12%) | 342 (67.86%) | |
| III | 271 (27%) | 136 (26.93%) | 135 (26.79%) | |
| Angioma thrombus | N = 505 (100(%)) | |||
| − | 717 (71%) | 357 (70.69%) | 360 (71.43%) | 0.85 |
| + | 292 (29%) | 148 (29.31%) | 144 (28.57%) | |
| Clinical stage | N = 505 (100(%)) | |||
| I | 64 (6%) | 39 (7.72%) | 25 (4.96%) | 0.21 |
| II | 265 (26%) | 138 (27.33%) | 127 (25.2%) | |
| III | 562 (56%) | 269 (53.27%) | 293 (58.13%) | |
| IV | 118 (12%) | 59 (11.68%) | 59 (11.71%) | |
| Lymph node status | N = 505 (100(%)) | |||
| − | 184 (18%) | 93 (18.42%) | 91 (18.06%) | 0.95 |
| + | 825 (82%) | 412 (81.58%) | 413 (81.94%) | |
| Mitosis | N = 505 (100(%)) | |||
| 1 | 317 (31%) | 158 (31.29%) | 159 (31.55%) | 0.33 |
| 2 | 629 (62%) | 321 (63.56%) | 308 (61.11%) | |
| 3 | 63 (6%) | 26 (5.15%) | 37 (7.34%) | |
| MP class | N = 505 (100(%)) | |||
| 1 | 67 (7%) | 24 (4.75%) | 43 (8.53%) | 0.09 |
| 2 | 231 (23%) | 123 (24.36%) | 108 (21.43%) | |
| 3 | 518 (51%) | 259 (51.29%) | 259 (51.39%) | |
| 4 | 190 (19%) | 96 (19.01%) | 94 (18.65%) | |
| 5 | 3 (0%) | 3 (0.59%) | 0 (0%) | |
| RCB class | N = 505 (100(%)) | |||
| I | 52 (5%) | 26 (5.15%) | 26 (5.16%) | 0.49 |
| II | 511 (51%) | 265 (52.48%) | 246 (48.81%) | |
| III | 446 (44%) | 214 (42.38%) | 232 (46.03%) | |
| ER | N = 505 (100(%)) | |||
| − | 289 (29%) | 137 (27.13%) | 152 (30.16%) | 0.32 |
| + | 720 (71%) | 368 (72.87%) | 352 (69.84%) | |
| PR | N = 505 (100(%)) | |||
| − | 363 (36%) | 174 (34.46%) | 189 (37.5%) | 0.35 |
| + | 646 (64%) | 331 (65.54%) | 315 (62.5%) | |
| KI67 | N = 505 (100(%)) | |||
| − | 140 (14%) | 79 (15.64%) | 61 (12.1%) | 0.12 |
| + | 869 (86%) | 426 (84.36%) | 443 (87.9%) | |
| HER2 | N = 505 (100(%)) | |||
| − | 663 (66%) | 341 (67.52%) | 322 (63.89%) | 0.25 |
| + | 346 (34%) | 164 (32.48%) | 182 (36.11%) | |
| Molecular | N = 505 (100(%)) | |||
| HR | 746 (74%) | 69 (13.66%) | 82 (16.27%) | 0.43 |
| HER2+ | 151 (15%) | 382 (75.64%) | 364 (72.22%) | |
| TN | 112 (11%) | 54 (10.69%) | 58 (11.51%) | |
| Tils | N = 505 (100(%)) | |||
| Low | 213 (21%) | 99 (19.6%) | 114 (22.62%) | 0.5 |
| Moderate | 604 (60%) | 308 (60.99%) | 296 (58.73%) | |
| High | 192 (19%) | 98 (19.41%) | 94 (18.65%) | |
| N | 1,009 | 505 | 504 |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2; Tils, tumor-infiltrating lymphocytes; −, negative; +, positive; HR, hormone receptor positive; HER2+, human epidermal growth factor 2 positive; TN, triple-negative breast cancer.